These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31884599)

  • 1. A Discovery with Potential to Revitalize Hammerhead Ribozyme Therapeutics for Treatment of Inherited Retinal Degenerations.
    Trujillo AJ; Myers JM; Fayazi ZS; Butler MC; Sullivan JM
    Adv Exp Med Biol; 2019; 1185():119-124. PubMed ID: 31884599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets.
    Yau EH; Butler MC; Sullivan JM
    Exp Eye Res; 2016 Oct; 151():236-55. PubMed ID: 27233447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy.
    Abdelmaksoud HE; Yau EH; Zuker M; Sullivan JM
    Exp Eye Res; 2009 May; 88(5):859-79. PubMed ID: 19094986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa.
    Sullivan JM; Pietras KM; Shin BJ; Misasi JN
    Mol Vis; 2002 Apr; 8():102-13. PubMed ID: 11961505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa.
    O'Neill B; Millington-Ward S; O'Reilly M; Tuohy G; Kiang AS; Kenna PF; Humphries P; Farrar GJ
    Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):2863-9. PubMed ID: 10967039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa.
    Drenser KA; Timmers AM; Hauswirth WW; Lewin AS
    Invest Ophthalmol Vis Sci; 1998 Apr; 39(5):681-9. PubMed ID: 9538873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribozyme knockdown of the gamma-subunit of rod cGMP phosphodiesterase alters the ERG and retinal morphology in wild-type mice.
    Liu J; Timmers AM; Lewin AS; Hauswirth WW
    Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3836-44. PubMed ID: 16186371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An allele-specific hammerhead ribozyme gene therapy for a porcine model of autosomal dominant retinitis pigmentosa.
    Shaw LC; Skold A; Wong F; Petters R; Hauswirth WW; Lewin AS
    Mol Vis; 2001 Jan; 7():6-13. PubMed ID: 11172137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribozymes in the age of molecular therapeutics.
    Bagheri S; Kashani-Sabet M
    Curr Mol Med; 2004 Aug; 4(5):489-506. PubMed ID: 15267221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
    Phylactou LA; Tsipouras P; Kilpatrick MW
    Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cleavage of viral RNA and inhibition of viral translation by hepatitis C virus RNA-specific hammerhead ribozyme in vitro.
    Ohkawa K; Yuki N; Kanazawa Y; Ueda K; Mita E; Sasaki Y; Kasahara A; Hayashi N
    J Hepatol; 1997 Jul; 27(1):78-84. PubMed ID: 9252077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of hammerhead ribozymes in the treatment of hyper-proliferative diseases.
    Grassi G; Dawson P; Guarnieri G; Kandolf R; Grassi M
    Curr Pharm Biotechnol; 2004 Aug; 5(4):369-86. PubMed ID: 15320768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribozymes as therapeutic tools for genetic disease.
    Phylactou LA; Kilpatrick MW; Wood MJ
    Hum Mol Genet; 1998; 7(10):1649-53. PubMed ID: 9735387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A structural analysis of in vitro catalytic activities of hammerhead ribozymes.
    Shao Y; Wu S; Chan CY; Klapper JR; Schneider E; Ding Y
    BMC Bioinformatics; 2007 Nov; 8():469. PubMed ID: 18053134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of structure in a long target RNA on ribozyme cleavage efficiency.
    Campbell TB; McDonald CK; Hagen M
    Nucleic Acids Res; 1997 Dec; 25(24):4985-93. PubMed ID: 9396806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa.
    Lewin AS; Drenser KA; Hauswirth WW; Nishikawa S; Yasumura D; Flannery JG; LaVail MM
    Nat Med; 1998 Aug; 4(8):967-71. PubMed ID: 9701253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and validation of therapeutic hammerhead ribozymes for autosomal dominant diseases.
    Fritz JJ; Gorbatyuk M; Lewin AS; Hauswirth WW
    Methods Mol Biol; 2004; 252():221-36. PubMed ID: 15017052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribozyme uses in retinal gene therapy.
    Hauswirth WW; Lewin AS
    Prog Retin Eye Res; 2000 Nov; 19(6):689-710. PubMed ID: 11029552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cleavage of full-length beta APP mRNA by hammerhead ribozymes.
    Denman RB
    Nucleic Acids Res; 1993 Aug; 21(17):4119-25. PubMed ID: 8371986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.